Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) and Perrigo (NYSE:PRGO – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.
Volatility & Risk
Eyepoint Pharmaceuticals has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.
Institutional and Insider Ownership
99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Eyepoint Pharmaceuticals | -10,994.73% | -135.81% | -108.35% |
| Perrigo | -41.85% | 11.25% | 4.08% |
Analyst Recommendations
This is a summary of recent recommendations for Eyepoint Pharmaceuticals and Perrigo, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eyepoint Pharmaceuticals | 1 | 6 | 4 | 0 | 2.27 |
| Perrigo | 1 | 4 | 1 | 0 | 2.00 |
Eyepoint Pharmaceuticals currently has a consensus target price of $25.70, suggesting a potential upside of 753.82%. Perrigo has a consensus target price of $19.33, suggesting a potential upside of 21.26%. Given Eyepoint Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Perrigo.
Earnings and Valuation
This table compares Eyepoint Pharmaceuticals and Perrigo”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Eyepoint Pharmaceuticals | $31.37 million | 8.27 | -$231.96 million | ($3.74) | -0.80 |
| Perrigo | $4.25 billion | 0.52 | -$1.43 billion | ($12.51) | -1.27 |
Eyepoint Pharmaceuticals has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Eyepoint Pharmaceuticals beats Perrigo on 10 of the 14 factors compared between the two stocks.
About Eyepoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
About Perrigo
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
